Imaging Immune Activation in COVID-19

NCT04815096 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Covid19
SARS-CoV Infection

Interventions

DRUG: [18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)

Sponsor

CellSight Technologies, Inc.

Collaborators

[object Object]